 | Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
 | Out- side |
| | | | |
|
| | | | |
Result : Searchterm 'Relaxation Effect' found in 1 term [ ] and 3 definitions [ ], (+ 17 Boolean[ ] results
| previous 16 - 20 (of 21) nextResult Pages : [1] [2 3 4 5] |  | |  | Searchterm 'Relaxation Effect' was also found in the following service: | | | | |
|  |  |
| |
|
(PS) Excitation technique applying repeated RF pulses in times comparable to or shorter than T1.
Incomplete T1 relaxation leads to reduction of the signal amplitude; there is the possibility of generating images with increased contrast between regions with different relaxation times.
Although partial saturation is also commonly referred to as saturation recovery, that term should properly be reserved for the particular case of partial saturation in which recovery after each excitation effectively takes place from true saturation.
A GRE sequence where α = 90° is identical to the partial saturation or saturation recovery pulse sequence.
It does not directly produce images of T1. However, since the measured signal will depend on T1, the method generates contrast between regions with different relaxation times. If T2 and/or T2 effects are minimized through the use of a short echo time TE, the result is a T1 weighted image. It is not a T1 image due to the possible presence of spin density and T2 effects as well as the nonlinear dependence on T1.
The change in signal from a region resulting from a change in the interpulse time, TR, can be used to calculate T1 for the region. | |  | | | | | | | |
|  | |  |  |  |
| |
|
( SPIO) Relatively new types of MRI contrast agents are superparamagnetic iron oxide-based colloids (median diameter greater than 50nm). These compounds consist of nonstoichiometric microcrystalline magnetite cores, which are coated with dextrans (in ferumoxide) or siloxanes (in ferumoxsil). After injection they accumulate in the reticuloendothelial system (RES) of the liver (Kupffer cells) and the spleen. At low doses circulating iron decreases the T1 time of blood, at higher doses predominates the T2* effect.
SPIO agents are much more effective in MR relaxation than paramagnetic agents. Since hepatic tumors either do not contain RES
cells or their activity is reduced, the contrast between liver and lesion is improved. Superparamagnetic iron oxides cause noticeable shorter T2 relaxation times with signal loss in the targeted tissue (e.g., liver and spleen) with all standard pulse sequences.
Magnetite, a mixture of FeO and Fe2O3, is one of the used iron oxides. FeO can be replaced by Fe3O4.
Use of these colloids as tissue specific contrast agents is now a well-established area of pharmaceutical development. Feridex®, Endorem™, GastroMARK®, Lumirem®, Sinerem®, Resovist® and more patents pending tell us that the last word in this area is not said.
Some remarkable points using SPIO:
•
A minimum delay of about 10 min. between injection (or infusion) and MR imaging, extends the examination time.
•
Cross-section flow void in narrow blood vessels may impede the differentiation from small liver lesions.
•
Aortic pulsation artifacts become more pronounced.
See also Superparamagnetism, Superparamagnetic Contrast Agents and Classifications, Characteristics, etc.. | |  | | • View the DATABASE results for 'Superparamagnetic Iron Oxide' (32).
| | | • View the NEWS results for 'Superparamagnetic Iron Oxide' (3).
| | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
|  | |  |  |  |
| |
|
| | | | | | | | | | | • View the DATABASE results for 'Time of Flight Angiography' (11).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
|  |  | Searchterm 'Relaxation Effect' was also found in the following service: | | | | |
|  |  |
| |
|
Categories of negative oral contrast agents:
Negative oral contrast media are usually based on superparamagnetic particles and act by inducing local field inhomogeneities, which results in shortening of both T1 and T2 relaxation times. Superparamagnetic contrast agents have predominant T2 weighted effects.
Biphasic contrast media are agents that have different signal intensities on different sequences, depending on the concentration at which they are used.
Suitable materials for oral contrast agents should have little or no absorption by the stomach or intestines, complete excretion, no motion or susceptibility artifacts, affordability, and uniform marking of the gastrointestinal tract.
Benefits of negative oral contrast agents are the reduction of ghosting artifacts caused by the lack of signal. Superparamagnetic iron oxides produce also in low concentrations a noticeable signal loss; but can generate susceptibility artifacts especially in gradient echo sequences. Perfluorochemicals do not dilute in the bowel because they are not miscible with water.
High cost, poor availability, and limited evaluations of side effects are possible disadvantages.
Negative oral contrast agents are used e.g., in MRCP, where the ingestion of 600-900 ml of SPIO cancels out the signal intensity of the lumen (in addition after the injection of a gadolinium-based contrast medium, the enhancement of the inflammatory tissues is clearer seen), and in MR abdominal imaging of Crohn's disease in combination with mannitol.
| |  | | • View the DATABASE results for 'Negative Oral Contrast Agents' (7).
| | | | Further Reading: | Basics:
|
|
| |
|  | |  |  |  |
| |
|
Eovist® (other brand name Primovist™) is a organ specific MRI contrast agent for the imaging, detection and characterization of liver conditions, including liver tumors, cysts, as well as other malignant and benign lesions. It is a water-soluble ethoxybenzyl derivative of Gd-DTPA. This compound is taken up by the hepatocytes (approximately 30% of the dose goes to the hepatocytes) and is equally excreted renal and biliary in humans. Excretion of Gd-EOB-DTPA in the bile may also permit visualization of both the gall bladder and the bile ducts.
Eovist® brightens the signal of T1 weighted MR images immediately after contrast administration.
Dynamic and accumulation phase imaging can also be performed after bolus injection of Eovist®. The hepatocytes uptake will increase the signal intensity of normal liver parenchyma at 10 to 20 minutes after injection. This results in improved lesion-to-liver contrast because malignant tumors (metastases, the majority of hepatocellular carcinomas) do not contain either hepatocytes or their functioning is hampered. WARNING:
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m 2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
See also Drug Development and Approval Process USA, Contrast Medium, Hepatobiliary Contrast Agents, Tumor Specific Agents and Molecular Imaging.
Drug Information and Specification
T1, Predominantly positive enhancement
PHARMACOKINETIC
50% hepatobiliary, 50% renal excretion
DOSAGE
12,5 - 25 µmol/kg
PREPARATION
Finished product
DEVELOPMENT STAGE
For sale
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT!
| |  | | • View the DATABASE results for 'Eovist®' (4).
| | | | Further Reading: | Basics:
|
|
| |
|  | |  |  |
|  | | |
|
| |
 | Look Ups |
| |